Literature DB >> 26516155

Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients.

Tongmeng Yan1, Linlin Lu2, Cong Xie1, Jiamei Chen2, Xiaojuan Peng1, Lijun Zhu2, Ying Wang2, Qiang Li1, Jian Shi1, Fuyuan Zhou3, Ming Hu4, Zhongqiu Liu5.   

Abstract

This study aims to systematically determine the activities and expressions of cytochrome P450s (CYP) in hepatocellular carcinoma (HCC) patients to support their optimal use in personalized treatment of HCC. Activities of seven major drug-metabolizing CYP enzymes (CYP1A2, 2A6, 2C8, 2C9, 2D6, 2E1, and 3A4) were determined in tumors and pericarcinomatous tissues harvested from 26 patients with hepatitis B virus-positive HCC using probe substrates. Protein and mRNA levels of these CYPs were also measured using isotope label-free LC/MS-MS method and real-time PCR, respectively. Maximal metabolic velocity (Vmax) of CYP probe substrates was decreased by 2.5- to 30-fold in tumor microsomes, accompanied by a corresponding decrease in their protein and mRNA expression levels. However, Km values and turnover numbers of substrates in tumor microsomes were not changed. High correlations between activities and CYP protein levels were also observed, but the correlation between activities and mRNA levels was often poor. There was a major decrease in the degree of correlation in CYP expression in tumor tissues, suggesting that CYP expression levels are greatly disrupted by the tumorigenic process. Our unprecedented systemic study of the effects of HCC on CYPs demonstrated that activities of CYPs were seriously impaired and their expression patterns were severely altered by HCC. We proposed that determination of the CYP protein expression profile by LC/MS-MS in each patient is a promising approach that can be clinically used for individualized treatment of HCC. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26516155      PMCID: PMC4674380          DOI: 10.1158/1535-7163.MCT-15-0274

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  37 in total

1.  Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies.

Authors:  Daniel B Brown; Jean-Francois H Geschwind; Michael C Soulen; Steven F Millward; David Sacks
Journal:  J Vasc Interv Radiol       Date:  2006-02       Impact factor: 3.464

2.  Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma.

Authors:  H Raunio; R Juvonen; M Pasanen; O Pelkonen; P Pääkkö; Y Soini
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

Review 3.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.

Authors:  J B Houston; K E Kenworthy
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

4.  Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).

Authors:  Renumathy Dhanasekaran; David A Kooby; Charles A Staley; John S Kauh; Vinit Khanna; Hyun S Kim
Journal:  J Surg Oncol       Date:  2010-05-01       Impact factor: 3.454

5.  Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection.

Authors:  Hirotaka Kawakami; Sumio Ohtsuki; Junichi Kamiie; Takashi Suzuki; Takaaki Abe; Tetsuya Terasaki
Journal:  J Pharm Sci       Date:  2010-06-16       Impact factor: 3.534

Review 6.  Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond.

Authors:  Xiaojuan Chai; Su Zeng; Wen Xie
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-01-17       Impact factor: 4.481

Review 7.  Drug metabolism by tumours: its nature, relevance and therapeutic implications.

Authors:  Michael Michael; Margaret M Doherty
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-12       Impact factor: 4.481

Review 8.  Cytochrome P450 pharmacogenetics and cancer.

Authors:  C Rodriguez-Antona; M Ingelman-Sundberg
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

Review 9.  Cytochrome P450 enzymes: novel options for cancer therapeutics.

Authors:  Morag C E McFadyen; William T Melvin; Graeme I Murray
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

10.  Comparison of RNA extraction methods from biofilm samples of Staphylococcus epidermidis.

Authors:  Angela França; Luís Dr Melo; Nuno Cerca
Journal:  BMC Res Notes       Date:  2011-12-30
View more
  20 in total

1.  Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption.

Authors:  Yu-Ju Chu; Hwai-I Yang; Hui-Chen Wu; Mei-Hsuan Lee; Jessica Liu; Li-Yu Wang; Sheng-Nan Lu; Chin-Lan Jen; San-Lin You; Regina M Santella; Chien-Jen Chen
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

2.  Role of miR-653 and miR-29c in downregulation of CYP1A2 expression in hepatocellular carcinoma.

Authors:  Martin Krkoška; Jana Nekvindová; Kateřina Nevědělová; Veronika Zubáňová; Lenka Radová; Jan Vondráček; Jarmila Herůdková; Ondřej Slabý; Igor Kiss; Lucia Bohovicová; Pavel Fabian; Zuzana Tylichová; Zdeněk Kala; Petr Kysela; Lenka Ostřížková; Vladimír Palička; Alena Hyršlová Vaculová
Journal:  Pharmacol Rep       Date:  2021-11-15       Impact factor: 3.024

Review 3.  Involvement of cytochrome P450 enzymes in inflammation and cancer: a review.

Authors:  Maria Carolina Stipp; Alexandra Acco
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-28       Impact factor: 3.333

4.  Population Pharmacokinetics of CC-122.

Authors:  Yiming Cheng; Jian Chen; Michael Pourdehnad; Simon Zhou; Yan Li
Journal:  Clin Pharmacol       Date:  2021-04-28

5.  mTOR/HDAC1 Crosstalk Mediated Suppression of ADH1A and ALDH2 Links Alcohol Metabolism to Hepatocellular Carcinoma Onset and Progression in silico.

Authors:  Kashif Rafiq Zahid; Shun Yao; Abdur Rehman Raza Khan; Umar Raza; Deming Gou
Journal:  Front Oncol       Date:  2019-10-04       Impact factor: 6.244

6.  Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.

Authors:  Jun Zhou; Qiang Wen; Sai-Fei Li; Yun-Fei Zhang; Na Gao; Xin Tian; Yan Fang; Jie Gao; Ming-Zhu Cui; Xiao-Pei He; Lin-Jing Jia; Han Jin; Hai-Ling Qiao
Journal:  Oncotarget       Date:  2016-08-02

7.  Development Of A Three-Gene Prognostic Signature For Hepatitis B Virus Associated Hepatocellular Carcinoma Based On Integrated Transcriptomic Analysis.

Authors:  Yao Yang; Qian Lu; Xuejun Shao; Banghui Mo; Xuqiang Nie; Wei Liu; Xianhua Chen; Yuan Tang; Youcai Deng; Jun Yan
Journal:  J Cancer       Date:  2018-04-30       Impact factor: 4.207

8.  The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma.

Authors:  Ryo Ashida; Yukiyasu Okamura; Keiichi Ohshima; Yuko Kakuda; Katsuhiko Uesaka; Teiichi Sugiura; Takaaki Ito; Yusuke Yamamoto; Takashi Sugino; Kenichi Urakami; Masatoshi Kusuhara; Ken Yamaguchi
Journal:  Oncotarget       Date:  2018-04-24

9.  Downregulation of CYP2A6 and CYP2C8 in Tumor Tissues Is Linked to Worse Overall Survival and Recurrence-Free Survival from Hepatocellular Carcinoma.

Authors:  Xiaojing Ren; Yuanyuan Ji; Xuhua Jiang; Xun Qi
Journal:  Biomed Res Int       Date:  2018-07-25       Impact factor: 3.411

10.  Assessment of Gold Nanoparticles-Inhibited Cytochrome P450 3A4 Activity and Molecular Mechanisms Underlying Its Cellular Toxicity in Human Hepatocellular Carcinoma Cell Line C3A.

Authors:  Kyoungju Choi; Hyun Joo
Journal:  Nanoscale Res Lett       Date:  2018-09-10       Impact factor: 4.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.